Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to rescue HIV patients when other treatments fail

NCT ID NCT00196625

Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three HIV drugs (amprenavir, lopinavir, and ritonavir) in patients whose current treatments are no longer working. The goal is to see if this new mix can lower the amount of HIV in the blood over 26 weeks. Participants are HIV-positive adults who have tried multiple previous therapies without success. The study compares two different doses of ritonavir to find the safest and most effective option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amprenavir, lopinavir, and ritonavir
What this could lead to
If successful, this combination could offer a new treatment option for people with HIV who have not responded to other therapies.
What could go wrong
This is a Phase 2 trial with only 100 participants, so results may not apply to everyone. The drugs can cause side effects and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

Start date

Nov 2000

Completion date

Feb 2002

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented HIV infection * CD4 cell count below 300/mm3 * Plasma HIV RNA over 30,000 copies/ml * Previously treated with 2 protease inhibitors and 1 non nucleoside analogue (except amprenavir, lopinavir) * Written informed consent Exclusion Criteria: * Biological abnormalities * Pregnancy * Alcool abuse * History of pancreatitis, hepatic failure * Acute HIV related infection * Chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infections

Contacts and locations

Locations

  • Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.